Second Pfizer Braftovi regimen shows benefit in mCRC
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF…
Oncology
-
-
Lilly’s Retevmo boosts event-free survival in early-stage NSCLC
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in…
-
WHO analysis shows four in ten cancers could be prevented
Globally, cancer is a leading cause of death and presents a significant challenge to public health. Despite major therapeutic advances…
-
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
-
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a…
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15…
-
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell…
-
JPM26: Roche’s rejuvenation strategy for the oncology and haematology portfolio
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
Immuneering is set to progress its lead oncology candidate, atebimetinib, to the next stage of clinical development in both first-line…
